NZ335997A - Substituted pyrimidine compounds for treating TNF and interleukin diseases - Google Patents

Substituted pyrimidine compounds for treating TNF and interleukin diseases

Info

Publication number
NZ335997A
NZ335997A NZ335997A NZ33599797A NZ335997A NZ 335997 A NZ335997 A NZ 335997A NZ 335997 A NZ335997 A NZ 335997A NZ 33599797 A NZ33599797 A NZ 33599797A NZ 335997 A NZ335997 A NZ 335997A
Authority
NZ
New Zealand
Prior art keywords
nr31r32
radicals
aryl
heteroaryl
interleukin
Prior art date
Application number
NZ335997A
Inventor
Ulrike D Spohr
Michael J Malone
Nathan B Mantlo
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority claimed from PCT/US1997/022390 external-priority patent/WO1998024782A2/en
Publication of NZ335997A publication Critical patent/NZ335997A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A compound of the general formula shown or a pharmaceutically acceptable salt thereof for treating diseases or conditions associated with inflammation. Preferably, the compound decreases the activity of tumour necrosis factor and/or interleukin. Some examples of the preferred compounds are also shown. Wherein; R1 and R2 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R1 and R2 is 0-4; R11 and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of (1) R30; (2) halo or cyano radicals; (3) -C(O)-R30, -C(O)-OR29, -C(O)-NR31R32 or -C(NR31)-NR31R32 radicals; (4) -OR29, -O-C(O)-R29, -O-C(O)-NR31R32 or -O-C(O)-NR33S(O)2-R30 radicals; (5) -SR29, -S(O)-R30, -S(O)2-R30, -S(O)2-NR31R32, -S(O)2NR33-C(O)-R30, -S(O)2-NR33-C(O)-OR30 or -S(O)2-NR33-C(O)NR31R32 radicals; or (6) -NR31R32, -NR33-C(O)-R29, -NR33-C(O)-OR30, -NR33-C(O)NR31R32, -NR33-C(NR31)-NR31R32, -NR33-S(O)2-R30 or -NR33S(O)2-NR31R32 radicals; provided that (1) R11 is other than a 4-pyridyl, 4pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;
NZ335997A 1996-12-05 1997-12-04 Substituted pyrimidine compounds for treating TNF and interleukin diseases NZ335997A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3212896P 1996-12-05 1996-12-05
US5095097P 1997-06-13 1997-06-13
US97605497A 1997-11-21 1997-11-21
PCT/US1997/022390 WO1998024782A2 (en) 1996-12-05 1997-12-04 Substituted pyrimidine compounds and their use

Publications (1)

Publication Number Publication Date
NZ335997A true NZ335997A (en) 2001-08-31

Family

ID=27364030

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ335997A NZ335997A (en) 1996-12-05 1997-12-04 Substituted pyrimidine compounds for treating TNF and interleukin diseases

Country Status (11)

Country Link
EP (1) EP0948497A2 (en)
CN (1) CN1246858A (en)
AR (1) AR048564A1 (en)
AU (1) AU733877C (en)
BG (1) BG65128B1 (en)
BR (1) BR9713850A (en)
CA (1) CA2274063C (en)
CZ (1) CZ296911B6 (en)
HU (1) HUP0001698A3 (en)
IL (1) IL130180A0 (en)
NZ (1) NZ335997A (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9502601A (en) * 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3
TWI265164B (en) 2001-09-21 2006-11-01 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
PL368816A1 (en) 2001-09-21 2005-04-04 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
TWI330183B (en) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
EP1340759A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
ZA200505258B (en) 2002-12-16 2006-09-27 Mitsubishi Pharma Corp 3-Substituted-4-pyrimidone derivatives
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
LT2629776T (en) * 2010-10-18 2017-11-10 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
TWI651310B (en) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 Triterpenoids and their medical use
WO2017073709A1 (en) * 2015-10-29 2017-05-04 あすか製薬株式会社 Pyrimidine derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759176A (en) * 1969-11-20 1971-05-19 Sandoz Sa PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND MEDICINAL PRODUCTS CONTAINING THESE DERIVES
US4438117A (en) * 1980-09-03 1984-03-20 E. I. Du Pont De Nemours And Company 2-Substituted thio-4,5-diarylpyrimidines
DE3319843A1 (en) * 1983-06-01 1984-12-06 Ali-Akbar Dipl.-Chem. Dr. 4300 Mülheim Pourzal Process for the preparation of pyrimidines from nitrile and alkynes
US4500533A (en) * 1983-06-22 1985-02-19 Eli Lilly And Company 2,4,5-Triaryl pyrimidines and a method of treating pain, fever, thrombosis, inflammation and arthritis
US5077142A (en) * 1989-04-20 1991-12-31 Ricoh Company, Ltd. Electroluminescent devices
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
BG65128B1 (en) 2007-03-30
HUP0001698A2 (en) 2001-04-28
CN1246858A (en) 2000-03-08
BG103512A (en) 2000-07-31
CZ9902015A3 (en) 1999-11-17
CZ296911B6 (en) 2006-07-12
AU733877C (en) 2003-05-08
CA2274063C (en) 2007-09-04
AU6012098A (en) 1998-06-29
BR9713850A (en) 2000-02-29
CA2274063A1 (en) 1998-06-11
IL130180A0 (en) 2000-06-01
EP0948497A2 (en) 1999-10-13
HUP0001698A3 (en) 2002-07-29
AU733877B2 (en) 2001-05-31
AR048564A1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
DK0636025T3 (en) Compounds suitable for the treatment of allergic and inflammatory diseases
CA2133439A1 (en) Compounds useful for treating allergic and inflammatory diseases
NO952396L (en) Amino-substituted pyrazoles with CRF antagonistic action
RU94031102A (en) Sulfides as endotheelin antagonists, and process for treating corresponding diseases
BG103179A (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
NO981528D0 (en) Substituted imidazoles with anti-cancer and cytokine inhibitor activity
ID27285A (en) BENZAMIDA DEPOSIT FOR TREATMENT DISEASE EXPANDED BY SITOKINA
NZ335997A (en) Substituted pyrimidine compounds for treating TNF and interleukin diseases
BG107195A (en) AMIDE COMPOUND AND ITS APPLICATION AS Rho KINASE INHIBITOR
BR9508057A (en) Compound
NZ305940A (en) N-(aroyl)glycine hydroxamic acid derivatives and related compounds that inhibit the production of tnf and are useful in treating asthma
ATE195128T1 (en) STEROID NITRITE/NITRATESTER DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY MEDICATIONS
TW345577B (en) A substituted tertiary amino compound or the salt thereof
ES8604256A1 (en) Azahomoerythromycin D derivative and intermediates therefor.
AU6822798A (en) Cycloalkylalkanecarboxamides and the production and use thereof
AU4268696A (en) Pyridine and pyrazinedicarboxylic-acid derivatives as cell proliferation regulators
AU7484791A (en) Method of treating diseases associated with elevated levels of interleukin 1
AU2275892A (en) Device for the concealed hanging of panels from load-bearing structures
ES8800255A1 (en) N6-benzopyrano- and benzothiopyrano-adenosines.
GB9002337D0 (en) Compounds useful in treating inflammatory bowel disease
ES8601137A1 (en) Derivatives of 2-(pyridyl-3)-2-phenylamino acetic acid, their preparation and their use as fungicides in agriculture
EP0784973A3 (en) Quinoxaline derivatives for treating tinnitus
MY109561A (en) Compounds for treating allegic and inflammatory diseases and inhibiting the production of tumor necrosis factor tnf
MX9709386A (en) ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS.
CA2413037A1 (en) Intermediates for producing antitumor indolopyrrolocarbazole derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: BY WAY OF CORRECTION

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)